AbbVie completes $10B senior notes offering to fund Apogee acquisition

AbbVie Inc.

Issued $10.0B aggregate principal across 9 tranches: floating rate notes due 2028 and fixed-rate notes from 4.500% due 2028 to 6.100% due 2066.
Net proceeds to fund cash consideration for Apogee Therapeutics acquisition and related fees; remainder for general corporate purposes.
Special mandatory redemption at 101% of principal if Apogee deal terminates before closing (excludes 2056 and 2066 notes).
Notes are unsecured, unsubordinated, rank equally with existing debt; make-whole redemption provisions apply to fixed-rate notes.
Offering completed August 18, 2026; supplemental indenture No. 13 filed with trustee U.S. Bank Trust Company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.